

Drug and Therapeutics Committee – Minutes – Confirmed

Date / Time	Thursday 8 th April 2021 8:15am – 9:30am
Venue	Webex
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Mrs W Hornsby, Senior Pharmacy Technician
Quorate: Yes / No	Yes
Attendance	Mr P O'Brien, Deputy Chief Pharmacist Dr S Raise, GP ER CCG Dr B Ali, GP Hull CCG Mr K McCorry, Medicines Optimisation Pharmacist, NECS Ms J Morgan, Professional Secretary, Principal Pharmacist – Formulary Dr O Ogunbambi, Consultant Rheumatologist Prof M Lind, Vice Chair, Professor of Oncology Dr H Klonin, Consultant Paediatrician Mr A Dawood, Consultant Anaesthetist Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Dr A Samson, Consultant Infectious Diseases
Guest	Mr S Gaines, Deputy Chief Pharmacist
Apologies	None

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
	<p>NatPSA: Emergency Steroid Alert Card (SEC)</p>	<p>SG attended to update the committee on the progress made so far to become compliant with the alert, which needs to be in place by 13th May. Four actions to comply with: 1)Review process' policies and digital systems 2)Prescribers undertaking regular reviews 3)Acute providers to review clerking documentation to ensure prompt in place to check for risk of adrenal crisis 4)Community and hospital pharmacies to source SEC</p> <p>Dr Aye is producing trust specific guidance that will come to D&T for approval once written. AM pointed out there is no evidence the card will work or reduce the number of deaths related to adrenal crisis in adults. The committee agreed the card would be useful for patients on high dose long term treatment of oral and parenteral steroids but questioned its value in patients receiving inhaled and topical treatments AM pointed out this may instil unnecessary fear in patients resulting in poor compliance with their medicines; with potential consequences on disease control.</p> <p>EPMA is only live on certain wards at HUTH and therefore digital prompts for the use of the card cannot be put in place for all patients. SG has been in talks with EPMA pharmacist and a wish list has been developed</p> <p>Drug chart to be updated with prompt to consider issuing a SEC and IDL will be updated with ESC prompt. HUTH pharmacists will add card to IDL if required.</p> <p>KMc said a message had been added to optimise Rx and NECS were supporting practices who are trying to implement the change.</p> <p>There were many concerns raised around patients who were receiving treatment from several different providers, were individual treatments would not quantify need for SEC but cumulatively they would,many of these patients could miss out on being given a SEC and accompanying advice.</p>	<p>SG and Dr Aye to attend OQC next week to discuss further</p> <p>DC to raise at OQC JM to add to escalation report to OQC</p>		DC/JM	5/21	

2021.04.01	Apologies	None this month					4/21
2021.04.02	Declarations of Interest	None					4/21
2021.04.03	Minutes of the previous meeting	Accepted as a true record	No further action				4/21
2021.04.04	Action Tracker	<p>NICE Guidance TA651 Naldemedine for treating opioid induced constipation – JM said there is not much interest in preparing a new product request for this item. Naldemedine is on formulary available via chairs approval until NPR received.</p> <p>New Product Requests Dr Khan has submitted treatment pathway, however the pathway suggests Acarizax is first line before Oralvac which is not what was discussed at committee and therefore is not what was approved by D&T. JM will discuss with Dr Khan</p> <p>Clinical Guidelines Calcitonin Gene Related Peptide Antagonists for Episodic Migraine was discussed at HERPC</p> <p>Tracker:New Product Request AM has written to Levosimendan applicant and advised them of the committees decision to reject. POB requested that AM discuss with him advice to give to oncall pharmacists after the meeting.</p> <p>Tracker:New Product Request POB to inform on call pharmacists that Levosimendan should not be supplied out of hours under any circumstances</p> <p>New Product Request AM has written to applicants and WH has updated the formulary</p> <p>New Product Request JM has discussed the possibility of type 1 diabetes guideline for primary care with endocrinology pharmacist and will discuss</p>	<p>No further action</p> <p>JM to discuss with Dr Khan</p> <p>Action complete</p> <p>Action complete</p> <p>AM to discuss with POB post meeting</p> <p>Action complete</p> <p>No further action</p>	<p>JM</p> <p>JM</p> <p>WH</p> <p>AM</p> <p>AM/ POB</p> <p>AM</p> <p>JM</p>	<p>5/21</p> <p>5/21</p> <p>4/21</p> <p>4/21</p> <p>5/21</p> <p>4/21</p> <p>4/21</p>		

		<p>further. This is a large piece of work which will take time to produce. Bring back to D&T once guideline written</p> <p>New Product Request AM has requested airway guidance committee be reinstated to review guidance for both COPD and Asthma</p> <p>New Product Request AM has written to dermatology and requested biologic pathway be updated</p> <p>New Product Request WH has added Filgotinib to July agenda for review</p> <p>Correspondence Received AM has written to Lung Health Check Programme lead who has agreed to withdraw advice on specific cardiovascular medicines.</p> <p>Issues to Escalate to OQC WH has added dissemination of information to April agenda</p>	Action complete		AM		4/21
			Action complete		AM		4/21
			Action complete		WH		4/21
			Action complete		AM		4/21
			Action complete		WH		4/21
2021.04.05	New Product Requests	<p>New Product Requests</p> <ul style="list-style-type: none"> None this month <p>Early Access to Medicines Pemigatanib for the treatment of cholangiocarcinoma, which is available through an MHRA EAMS scheme. ML said the request is justified as there are no other effective treatments available for this condition.</p>	AM to write to Prof Maraveyas with committees decision		AM		
2021.04.06	NICE Guidance	<p>TA680 Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma</p> <p>TA681 Baricitinib for treating moderate to severe atopic dermatitis</p> <p>NG190 Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing Contains recommendation for use of topical fusidic acid as first line therapy. The trust do not endorse this recommendation</p>	On formulary	No further action			4/21
			JM to ask Dr Zaman if trust wish to use	JM to discuss with Dr Zaman	JM	5/21	
			Noted	No further action			4/21

	<p>which it is believed will lead to increased resistance and the guideline will be discussed further by ACAT. Skin and soft tissue chapter is next to be reviewed of the primary care guidelines.</p>				
	CG57 Atopic eczema in under 12s: diagnosis and management	Noted	No further action		4/21
	TA682 Erenumab for preventing migraine – approved clinically in Oct 2018 but has never been commissioned. JM has updated the CGRP guideline to include erenumab which is on agenda for discussion.	Noted	No further action		4/21
	TA683 Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer –already on formulary	Noted	No further action		4/21
	TA 684 Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease – already on formulary	Noted	No further action		4/21
	NG191 COVID-19 rapid guideline: managing COVID-19	Noted	No further action		4/21
	NG80 Asthma: diagnosis, monitoring and chronic asthma management	Noted	No further action		4/21
	TA685 Anakinra for treating Still's disease – already on formulary	Noted	No further action		4/21
	TA686 Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)	Noted	No further action		4/21
	TA687 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy – already on formulary	Noted	No further action		4/21
	TA688 Selective internal radiation therapies for treating hepatocellular carcinoma – does not include use of any medicines	Noted	No further action		4/21

2021.04.07	MHRA Drug Safety Update	March 2021 Bendamustine (Levact) : increased risk of non melanoma skin cancer and progressive multifocal encephalopathy Covid 19: Vaccines and Medicines Updates for March 2021	Noted	No further action			4/21
2021.04.08	Minutes SMPC	January 2021 – short meeting updates to new drug chart discussed	Noted	No further action			4/21
2021.04.09	Minutes from HERPC	January 2021 – new palliative care guidelines for primary care discussed	Noted	No further action			4/21
2021.04.10	Regional Medicines Optimisation Committees	Shared Care Guidance This guidance is for discussion at HERPC as it relates to recommendations for shared care frameworks. JM agreed to attend rheumatology governance to discuss implementation.	Noted	No further action			4/21
2021.04.11	Clinical Guidelines	Inpatient vaccination plan So far 25 inpatients have been vaccinated these are all long-term patients. It was suggested that HUTH could send out letters to patients with planned admissions recommending they log on to the NHS website and book on for a vaccination before admission.	Approved	No further action			4/21
		CGRP Antagonist Guideline Updated to include Erenumab and reworded to differentiate between episodic and chronic treatments	Approved	No further action			4/21
2021.04.12	Dissemination of Information Across All Healthcare Groups /Providers	Add to agenda for discussion in May.	WH to add to May agenda		WH	5/21	
2021.04.13	D&T Attendance 20/21	Noted	No further action				4/21

2021.04.14	D&T New Product Requests 20/21	Noted	No further action				4/21
2021.04.15	Correspondence received	<p>Lung Health Check Letter – response Dr Boff from Scunthorpe replied to the chairs letter and agreed to withdraw recommendations for specific cardiac prophylactic drugs and to recommend to check for cardiovascular risk.</p> <p>JM was asked about the possibility of obtaining Filgotinib via an early access scheme for £1 a pack for a specific patient. This is a CCG commissioned item, thus the early access price needs to be approved by the CCGs. The CCGs commissioning committees do not meet until the first week in May to discuss; therefore this cannot be approved.</p> <p>There was a brief discussion around the 90 day implementation of NICE TAs and what the actual wording of this recommendation was.</p>	Noted				4/21
2021.04.16	Chairs approvals	None this month					4/21
2021.04.17	Issues to escalate to OQC	DC will discuss the Emergency Steroid Card Alert and the trusts response to this.	DC to discuss at OQC		DC	5/21	
2021.04.18	Any Other Business	<p>Methylcellulose has been discontinued – agreed to remove from formulary.</p> <p>JM asked if the drugs on the CDF could be removed from the formulary and replaced with a link to the document as it was constantly being updated, the committee agreed.</p>	CDF to removed and link to website added		WH	5/21	
	Date and Time of Next Meeting	<p>Date: Thursday 13th May 2021 Time: 8.15am-9.30am Venue: WEBEX</p>					